VTGN

Vistagen Therapeutics Inc. (VTGN) | Rumor.io

Vistagen Therapeutics

VTGN

Attention (50-day avg)0%

Attention rank (50-day avg)#927

Bullish sentiment (50-day avg)83%

Price to earnings ratio-0.16

Market capitalization13.3M

Earnings per share-1.66

Dividend yield (TTM)—

Revenue (annual)1.3M

Net income (annual)-69.7M

Social

What share of all stock conversation is about VTGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.02% +0.02	0% +0	0% +0

Sep 28

VistaGen Therapeutics' ($VTGN) stock price is up nearly 10% despite the Nasdaq being in the red, with the company's liquidation of a position last week being seen as a foolish move.
The company is expected to receive FDA guidance soon regarding its lead product, LSAS, with a Phase 3 path being discussed; this is seen as a compelling risk/reward opportunity at current prices.
VistaGen's fasedienol, a nasal spray for social anxiety, has shown encouraging recent data and a proposed new Phase 3 path being discussed with the FDA, with the potential for a serious revaluation of the stock if FDA feedback is favorable.

Generated by AI

Sentiment

Of the messages about VTGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +31.58	86.01% +15.04	84.56% +4.82	82.19% -7.56
Bearish	0% -31.58	13.99% -15.04	15.44% -4.82	17.81% +7.56

Bullish· Sep 24

The company's Phase 3 results have been successful, which could lead to a significant increase in its stock price.
There are multiple trials in the pipeline that show promising news, which could lead to a breakout in the company's stock price.
The company has a unique delivery system and two great drugs in its pipeline, which could lead to a buyout and significant gains for investors.

Bearish· Sep 24

The stock finished around $0.295, down 19.9% on the day, with a late-day breakdown and sellers taking control.
The immediate line in the sand is at $0.295, with the first reclaim zone at $0.30-$0.305 and a bigger target at $0.32.
The stock is considered a scam and a disaster, with some predicting a further drop to $0.27 or lower.

Generated by AI

Topics

Of the messages about VTGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	46.25%	70.55%	60.95%
Technical Analysis	0%	51.25%	28.08%	25.81%
Earnings	0%	0%	0%	2.06%
Analysts	0%	2.5%	1.37%	10.98%
Controversies	0%	0%	0%	0.21%
Macro	0%	0%	0%	0%

Earnings· Feb 12

VistaGen Therapeutics reported its third quarter fiscal 2018 financial results, but the Q4 EPS was not disclosed.
The company's financial performance for Q3 2018 was highlighted in the report.
VistaGen Therapeutics' financial results for Q3 2018 were made public.

Analysts· Dec 7

Jefferies analyst Andrew Tsai upgraded VTGN to Buy from Hold with a price target of $15, citing 50-60% confidence in FDA approval for its lead asset fasedienol.
Jefferies' upgrade was followed by a 12.9% increase in VTGN's stock price, with the company's shares jumping 7.2% on the news.
William Blair and Stifel also maintain positive coverage of VTGN, with price targets of $14 and $12, respectively, suggesting positive sentiment among analysts.

Announcements· Sep 5

Vistagen Therapeutics, Inc. (VTGN) has entered into an exclusive negotiation agreement with Fuji Pharma Co. to develop and commercialize its PH80 nasal spray in Japan for the treatment of moderate to severe hot flashes.
Fuji will make a non-refundable payment of $1.5 million to Vistagen to secure a time-limited exclusive negotiation period.
Vistagen's PH80 has demonstrated statistically significant results in reducing hot flashes and their severity in a recent Phase 2A study, which may contribute to the potential value of the company in the future.

Technical Analysis· Aug 10

The stock's phase 3 positive results could lead to multi-billion dollar revenue and a potential FDA approval, with a $30 price target and strong hold from Maxim.
The stock has formed a textbook retracement with support, indicating an upward trend, and its MACD and BB indicators are in a positive position.
The stock's recent price action has formed a potential bear flag pole, and a watch is being kept for a wedge breakout, with the possibility of a bounce at a specific price level.

Generated by AI

Community

Of the messages about VTGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	80%	29.55%	34.9%	65.98%
Newcomers	20%	70.45%	65.1%	34.02%

Regulars· Sep 24

The PALISADE-4 Phase 3 trial for fasedienol in social anxiety disorder showed a statistically significant benefit in the "very severe" subgroup, despite the overall study missing its primary endpoint.
The FDA meeting news is the next catalyst for the company, with potential feedback from the agency that could form the efficacy package for an NDA, and the FDA minutes are expected before the end of October.
The company is showing signs of a rebound from $0.26, driven by a drop in USO following the easing of tensions in the Strait of Hormuz, and the CEO's decision to use the SUDS endpoint instead of LSAS may have contributed to the delay.

Newcomers· Sep 24

The newcomer is optimistic about the asset's potential, citing the company's recent Phase 3 results and expecting the stock to trade over $1.00.
The newcomer believes the asset is undervalued, pointing to the company's promising pipeline of trials and the recent success of a similar stock, #Jazz.
The newcomer is focused on the asset's short-term price movement, discussing the possibility of a run-up to $0.50 or $1.00, and speculating about the company's future growth prospects.

Generated by AI

News

Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder

5d agofinance.yahoo.com

Vistagen presents exploratory data on social anxiety treatment

5d agoInvesting.com

12 Health Care Stocks Moving In Wednesday's Intraday Session - Artelo Biosciences (NASDAQ:ARTL), Vistagen

Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics (NASDAQ:VTGN) shares

6d agoBenzinga

Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data - Vistagen Therapeutics (NASDAQ:VTGN)

Vistagen reports positive preliminary Phase 3 data showing fasedienol nasal spray reduces social anxiety with strong safety results.

6d agoBenzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - IM Cannabis (NASDAQ:IMCC), Vistagen Ther

Gainers IM Cannabis (NASDAQ:IMCC) stock rose 56.3% to $6.47 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Vistagen Therapeutics (NASDAQ:VTGN) shares increased by

6d agoBenzinga

Top Premarket Gainers

Vistagen Therapeutics (VTGN) shares were up 68% in Wednesday premarket activity after the company an

7d agoYahoo Finance

Also Discussed

Investors talking about VTGN also mention

#	Name	Attention
1	Relmada Therapeutics Inc.RLMD	0%0
2	WRNT - Warrantee Inc. American Depositary Shares	——
3	ICCT - iCoreConnect Inc.	——
4	AXLA - Axcella Health Inc.	——
5	REalloys Inc.BLBX	0%0
6	SAGE - Sage Therapeutics, Inc.	——
7	Foxx Development Holdings Inc.FOXX	0%new
8	Rezolute Inc.RZLT	0%+0
9	TCTM - TCTM Kids IT Education Inc.	——
10	BNOX - Bionomics Limited	——

Vistagen Therapeutics Inc.

Healthcare
Biotechnology

Vistagen Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on neuropsychiatric and neurological disorders. The company develops intranasal product candidates known as pherines, designed to act through nose-to-brain neurocircuitry and support rapid, targeted delivery within the central nervous system. Its current pipeline centers on treatments for conditions such as social anxiety disorder, major depressive disorder, and menopause-related vasomotor symptoms. Vistagen Therapeutics Inc. also pursues research and development using human neuroscience and clinical testing to advance non-systemic therapeutic approaches. Headquartered in South San Francisco, California, the company operates in the biotechnology sector and works to address unmet needs across mental health and women’s health markets.

Website

Location

343 Allerton Avenue

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about VTGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.02% +0.02	0% +0	0% +0

Sep 28

VistaGen Therapeutics' ($VTGN) stock price is up nearly 10% despite the Nasdaq being in the red, with the company's liquidation of a position last week being seen as a foolish move.
The company is expected to receive FDA guidance soon regarding its lead product, LSAS, with a Phase 3 path being discussed; this is seen as a compelling risk/reward opportunity at current prices.
VistaGen's fasedienol, a nasal spray for social anxiety, has shown encouraging recent data and a proposed new Phase 3 path being discussed with the FDA, with the potential for a serious revaluation of the stock if FDA feedback is favorable.

Generated by AI

Sentiment

Of the messages about VTGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +31.58	86.01% +15.04	84.56% +4.82	82.19% -7.56
Bearish	0% -31.58	13.99% -15.04	15.44% -4.82	17.81% +7.56

Bullish· Sep 24

The company's Phase 3 results have been successful, which could lead to a significant increase in its stock price.
There are multiple trials in the pipeline that show promising news, which could lead to a breakout in the company's stock price.
The company has a unique delivery system and two great drugs in its pipeline, which could lead to a buyout and significant gains for investors.

Bearish· Sep 24

The stock finished around $0.295, down 19.9% on the day, with a late-day breakdown and sellers taking control.
The immediate line in the sand is at $0.295, with the first reclaim zone at $0.30-$0.305 and a bigger target at $0.32.
The stock is considered a scam and a disaster, with some predicting a further drop to $0.27 or lower.

Generated by AI

Topics

Of the messages about VTGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	46.25%	70.55%	60.95%
Technical Analysis	0%	51.25%	28.08%	25.81%
Earnings	0%	0%	0%	2.06%
Analysts	0%	2.5%	1.37%	10.98%
Controversies	0%	0%	0%	0.21%
Macro	0%	0%	0%	0%

Earnings· Feb 12

VistaGen Therapeutics reported its third quarter fiscal 2018 financial results, but the Q4 EPS was not disclosed.
The company's financial performance for Q3 2018 was highlighted in the report.
VistaGen Therapeutics' financial results for Q3 2018 were made public.

Analysts· Dec 7

Jefferies analyst Andrew Tsai upgraded VTGN to Buy from Hold with a price target of $15, citing 50-60% confidence in FDA approval for its lead asset fasedienol.
Jefferies' upgrade was followed by a 12.9% increase in VTGN's stock price, with the company's shares jumping 7.2% on the news.
William Blair and Stifel also maintain positive coverage of VTGN, with price targets of $14 and $12, respectively, suggesting positive sentiment among analysts.

Announcements· Sep 5

Vistagen Therapeutics, Inc. (VTGN) has entered into an exclusive negotiation agreement with Fuji Pharma Co. to develop and commercialize its PH80 nasal spray in Japan for the treatment of moderate to severe hot flashes.
Fuji will make a non-refundable payment of $1.5 million to Vistagen to secure a time-limited exclusive negotiation period.
Vistagen's PH80 has demonstrated statistically significant results in reducing hot flashes and their severity in a recent Phase 2A study, which may contribute to the potential value of the company in the future.

Technical Analysis· Aug 10

The stock's phase 3 positive results could lead to multi-billion dollar revenue and a potential FDA approval, with a $30 price target and strong hold from Maxim.
The stock has formed a textbook retracement with support, indicating an upward trend, and its MACD and BB indicators are in a positive position.
The stock's recent price action has formed a potential bear flag pole, and a watch is being kept for a wedge breakout, with the possibility of a bounce at a specific price level.

Generated by AI

Community

Of the messages about VTGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	80%	29.55%	34.9%	65.98%
Newcomers	20%	70.45%	65.1%	34.02%

Regulars· Sep 24

The PALISADE-4 Phase 3 trial for fasedienol in social anxiety disorder showed a statistically significant benefit in the "very severe" subgroup, despite the overall study missing its primary endpoint.
The FDA meeting news is the next catalyst for the company, with potential feedback from the agency that could form the efficacy package for an NDA, and the FDA minutes are expected before the end of October.
The company is showing signs of a rebound from $0.26, driven by a drop in USO following the easing of tensions in the Strait of Hormuz, and the CEO's decision to use the SUDS endpoint instead of LSAS may have contributed to the delay.

Newcomers· Sep 24

The newcomer is optimistic about the asset's potential, citing the company's recent Phase 3 results and expecting the stock to trade over $1.00.
The newcomer believes the asset is undervalued, pointing to the company's promising pipeline of trials and the recent success of a similar stock, #Jazz.
The newcomer is focused on the asset's short-term price movement, discussing the possibility of a run-up to $0.50 or $1.00, and speculating about the company's future growth prospects.

Generated by AI

Vistagen Therapeutics

Social

Sep 28

Bullish· Sep 24

Bearish· Sep 24

Earnings· Feb 12

Analysts· Dec 7

Announcements· Sep 5

Technical Analysis· Aug 10

Regulars· Sep 24

Newcomers· Sep 24

Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder

Vistagen presents exploratory data on social anxiety treatment

12 Health Care Stocks Moving In Wednesday's Intraday Session - Artelo Biosciences (NASDAQ:ARTL), Vistagen

Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data - Vistagen Therapeutics (NASDAQ:VTGN)

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - IM Cannabis (NASDAQ:IMCC), Vistagen Ther

Top Premarket Gainers

Also Discussed

Vistagen Therapeutics Inc.

Company Information

Location

Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder

Vistagen presents exploratory data on social anxiety treatment

12 Health Care Stocks Moving In Wednesday's Intraday Session - Artelo Biosciences (NASDAQ:ARTL), Vistagen

Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data - Vistagen Therapeutics (NASDAQ:VTGN)

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - IM Cannabis (NASDAQ:IMCC), Vistagen Ther

Top Premarket Gainers

Also Discussed

Social

Sep 28

Bullish· Sep 24

Bearish· Sep 24

Earnings· Feb 12

Analysts· Dec 7

Announcements· Sep 5

Technical Analysis· Aug 10

Regulars· Sep 24

Newcomers· Sep 24